{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dental-abscess/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"9bd34406-b8a3-5ab1-8a5d-3bd78925ef32","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field 175cf268-11ca-4d63-98c1-a6fe010045e5 --><h2>Clarithromycin</h2><!-- end field 175cf268-11ca-4d63-98c1-a6fe010045e5 -->","summary":"","htmlStringContent":"<!-- begin item d54d216f-0314-41ca-8796-a6fe010044d8 --><!-- end item d54d216f-0314-41ca-8796-a6fe010044d8 -->","topic":{"id":"d9ce8bcf-6a30-56c3-9028-f291f9b80333","topicId":"7e8f6d78-0b6f-4813-baa8-3184010dd768","topicName":"Dental abscess","slug":"dental-abscess","lastRevised":"Last revised in October 2018","chapters":[{"id":"82801101-5e68-547d-8c3c-4ad6ec3b91b9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"92e4cbdc-7fa7-574b-bb17-97199587fe2d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e4034c8e-5cd0-5dc4-ba1d-f3ca1fe09c21","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84291395-fd80-58ef-a144-855cbf9b7b46","slug":"changes","fullItemName":"Changes"},{"id":"07b47e29-f600-5771-917c-4d6cd9135ed2","slug":"update","fullItemName":"Update"}]},{"id":"e967b353-dcf8-5e71-a9b0-95ca162918b8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"244fc23b-f275-5565-b50c-dca750baa8d9","slug":"goals","fullItemName":"Goals"},{"id":"1eb55d27-8795-5d81-8b81-4b4b6b7efa18","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2423d7f3-a323-50a3-8bbd-9664897bccd4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f5780547-92b5-5ede-a620-c7cf34a41b3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e9cfdeb1-ec38-5e0d-b03e-0acd118058b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"fa0115e4-0051-5374-8fae-1e1fbec27b97","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5f20011b-3e94-5351-a2a6-2a9565c42d7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69b7a1cd-7d22-52ab-b602-3a0c4bfbb4d4","slug":"definition","fullItemName":"Definition"},{"id":"617d13f2-34cd-5fd2-8869-198c3a3d5f06","slug":"causes","fullItemName":"Causes"},{"id":"777f9b6b-175c-5308-bba6-916d89e075b3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"cf5def0d-1ffd-5d57-b788-273fc8248d5c","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"735fc661-47ce-5a94-a29f-f0076c17ce88","slug":"complications","fullItemName":"Complications"}]},{"id":"df647f07-2727-5ac9-b87c-5adcdcf79bd6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b2a41850-a8dc-5b90-a7c5-4f2216c54cd2","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d97daa33-59c0-5607-a1fe-03238b7b333f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"6b0a689b-1ec7-5794-a5f0-b4efc84acfd2","fullItemName":"Management","slug":"management","subChapters":[{"id":"e6487762-ae28-5710-865a-01603c95176a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86cee72a-afc7-5150-92f0-6ff0e90b0172","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a9ed2df0-8168-51d7-b8e8-f5bb7c662d36","slug":"analgesics","fullItemName":"Analgesics"},{"id":"c8a5d71d-6f87-5315-aa1f-59791511dafe","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9bd34406-b8a3-5ab1-8a5d-3bd78925ef32","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"03d761c0-a760-5547-8910-97a65535bf94","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"91946ef3-8703-52eb-ba0a-b9cabca622e5","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"}]},{"id":"9c1469e7-dbca-5eaa-b2cd-29e127addf9a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aac7c7e4-eb79-5922-8ea7-3250adfae6b3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5aabd034-b3df-5bf4-93c1-30787cb35e17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6420441b-a18d-5bdb-a114-17409f623a23","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"65e26e16-4508-5e81-a8bf-307836e310cd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0aba46be-7078-5b8a-8557-56574cc69291","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2d089d7b-e753-518e-95f6-04243be55427","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f724f89d-9d85-5d8b-9675-d551cbf4aa5e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"86cee72a-afc7-5150-92f0-6ff0e90b0172","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"545c4778-57f1-5bb4-9f18-44c840dd60b2","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 51afda25-9250-42fd-b448-a71900efe3b8 --><h3>What dose of clarithromycin should I prescribe?  </h3><!-- end field 51afda25-9250-42fd-b448-a71900efe3b8 -->","summary":"","htmlStringContent":"<!-- begin item 3cecf7f9-71ac-48e4-8326-a71900efe439 --><!-- begin field bc67f572-d5a5-422b-a020-a71900efe3b8 --><ul><li>For dental abscess, prescribe a 5 day course of clarithromycin (review after 3 days): <ul><li>Adult: 500 mg twice a day. </li><li>For a child aged 1 month to 12 years:<ul><li>Bodyweight less than 8 kg 7.5 mg/kg twice daily. </li><li>Bodyweight 8–11 kg 62.5 mg twice daily. </li><li>Bodyweight 12–19 kg 125 mg twice daily. </li><li>Bodyweight 20–29 kg 187.5 mg twice daily. </li><li>Bodyweight 30–40 kg 250 mg twice daily. </li></ul></li><li>Child 12–18 years of age: 250 mg twice daily. </li><li>Note that clarithromycin tablets are not licensed for use in children under 12 years. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">PHE, 2017</a>]</p><!-- end field bc67f572-d5a5-422b-a020-a71900efe3b8 --><!-- end item 3cecf7f9-71ac-48e4-8326-a71900efe439 -->","subChapters":[]},{"id":"5e37b22d-b279-5c98-9d0e-ad3374849b35","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8936224a-1cc0-46a6-a9ee-a6fe01062b9a --><h3>What cautions and contraindications are associated with clarithromycin?</h3><!-- end field 8936224a-1cc0-46a6-a9ee-a6fe01062b9a -->","summary":"","htmlStringContent":"<!-- begin item e7b8c0b2-4f52-4313-80d5-a6fe01062a3b --><!-- begin field 31cf9e79-f08e-4eee-91b6-a6fe01062b9a --><ul><li><strong>Do not prescribe clarithromycin</strong> to people with:<ul><li>Known hypersensitivity to clarithromycin or other macrolide antibiotics.</li><li>A history of QT prolongation or ventricular arrhythmia, including Torsade de Pointes.</li><li>Hypokalaemia.</li><li>Severe hepatic failure.</li></ul></li><li><strong>Prescribe clarithromycin with caution</strong> in people with:<ul><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.</li><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — clarithromycin is principally excreted by the liver. </li><li>Moderate to severe renal impairment.</li><li>Use half the normal dose in severe renal impairment (eGFR less than 30mL/min) for a maximum duration of 14 days. Avoid Klaricid XL<sup>® </sup>(clarithromycin prolonged release once daily tablets) in people with eGFR less than 30 mL/min.</li><li>Conditions that predispose to QT interval prolongation, such as electrolyte disturbances and people taking drugs that prolong the QT interval  — macrolides can also prolong the QT interval, increasing the risk of Torsades de Pointes arrhythmia. </li><li>Myasthenia gravis — macrolide antibiotics may aggravate weakness symptoms of people with myasthenia gravis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">BNF 72, 2016</a>] </p><!-- end field 31cf9e79-f08e-4eee-91b6-a6fe01062b9a --><!-- end item e7b8c0b2-4f52-4313-80d5-a6fe01062a3b -->","subChapters":[]},{"id":"a0ca0bdf-3776-512e-9365-cc604f416765","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1de82b59-3c2c-4839-9ac8-a6fe01065174 --><h3>What are the adverse effects of clarithromycin?</h3><!-- end field 1de82b59-3c2c-4839-9ac8-a6fe01065174 -->","summary":"","htmlStringContent":"<!-- begin item 2586bdfd-fc52-41e8-b25c-a6fe010650af --><!-- begin field b46aa377-4f20-426b-9ec5-a6fe01065174 --><ul><li>The most common adverse effects are gastrointestinal — such as nausea, vomiting, dyspepsia, and diarrhoea.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with clarithromycin.</li><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Less common adverse effects include rash and hepatoxicity.</li><li>Very rarely, QT prolongation, ventricular tachycardia, and Torsade de Pointes arrhythmia have been reported.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">BNF 72, 2016</a>] </p><!-- end field b46aa377-4f20-426b-9ec5-a6fe01065174 --><!-- end item 2586bdfd-fc52-41e8-b25c-a6fe010650af -->","subChapters":[]},{"id":"ccf6dbf8-abfa-56dc-9639-0b401642c963","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b8a7d94d-dab4-40d2-b34a-a6fe01066f3b --><h3>What drug interactions are important with clarithromycin?</h3><!-- end field b8a7d94d-dab4-40d2-b34a-a6fe01066f3b -->","summary":"","htmlStringContent":"<!-- begin item 3c7f7ce7-4b83-445f-8334-a6fe01066e61 --><!-- begin field 5e6916c3-c83f-4d80-9d70-a6fe01066f3b --><ul><li><strong>Drug interactions with clarithromycin include:</strong><ul><li><strong>Pimozide </strong>— do not prescribe with clarithromycin as concurrent use may result in QT prolongation, cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes.</li><li><strong>Ergotamine and dihydroergotamine</strong> — do not prescribe with clarithromycin as concurrent use may result in acute ergot toxicity. </li><li><strong>Colchicine </strong>— avoid concomitant administration as it may increase the risk of colchicine toxicity.</li><li><strong>Carbamazepine</strong> — monitor carbamazepine levels within 3–5 days of starting clarithromycin, and adjust dose accordingly. Clarithromycin can increase carbamazepine levels, causing carbamazepine toxicity (may present as nausea and vomiting, ataxia, and drowsiness).</li><li><strong>Other drugs that prolong the QT interval</strong> — if possible, avoid giving clarithromycin to a person who is already taking a drug that can potentially prolong the QT interval.</li><li><strong>Statins</strong> — there is an increased risk of myopathy.<ul><li>For simvastatin — do not prescribe clarithromycin to a person taking simvastatin. </li><li>For atorvastatin — avoid concurrent use with clarithromycin if possible. </li><li>For pravastatin — prescribe clarithromycin with caution and advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>Other statins — clinically significant interaction with clarithromycin is not expected for rosuvastatin and fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.<strong> </strong></li></ul></li><li><strong>Warfarin</strong> — increase frequency of monitoring of the international normalized ratio (INR) when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. Clarithromycin may enhance the effect of warfarin. </li><li><strong>Oral hypoglycaemic drugs and insulin</strong> — the concurrent use of clarithromycin and antidiabetic drugs (such as sulphonylureas and/or insulin) can result in significant hypoglycaemia.</li><li><strong>Calcium channel blockers (CCBs)</strong> — due to an increased risk of hypotension, caution is advised with the concurrent use of clarithromycin and CCBs metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of clarithromycin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">Preston, 2016</a>]</p><!-- end field 5e6916c3-c83f-4d80-9d70-a6fe01066f3b --><!-- end item 3c7f7ce7-4b83-445f-8334-a6fe01066e61 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}